Please login to the form below
Pneumococcal vaccine
This page shows the latest Pneumococcal vaccine news and features for those working in and with pharma, biotech and healthcare.
Pfizer to evaluate its pneumococcal vaccine alongside COVID-19 booster jab
Pfizer has launched a new study of its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) along with a booster dose of its BioNTech-partnered COVID-19 jab. ... 20vPnC includes capsular polysaccharide conjugates for the 13 serotypes in Pfizer’s
Latest news
-
Merck wins speedy FDA review for 15-valent pneumococcal vaccine
Merck &Co (MSD) has been given a fast-track designation for its next-generation 15-valent pneumococcal conjugate vaccine candidate V114. ... If approved, Merck’s V114 will be a close competitor of Pfizer's Prevnar-13, although Pfizer is seeking to
-
Merck submits 15-valent pneumococcal vaccine candidate to EMA and FDA
For more than a century, Merck inventors have developed vaccines that help tackle some of society’s biggest public health challenges, and that heritage is reflected today in our pneumococcal vaccine ... Pfizer also announced results from a
-
Keytruda growth helps Merck to offset COVID-19 impact in Q3
The growth in profits was mainly due to increasing demand for certain drugs, including its blockbuster checkpoint inhibitor Keytruda (pembrolizumab), and its bacterial pneumonia vaccine. ... While sales of its papillomavirus vaccine Gardasil declined due
-
Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win
New-generation shot could protect franchise from rival Merck &Co. Pfizer says it could be on course to file for approval of its new generation pneumococcal conjugate vaccine in the US ... Pneumococcal disease is caused by Streptococcus pneumoniae, and
-
Solid Q1 results lift Pfizer as it waits for pipeline boost
Pfizer’s Prevnar pneumococcal vaccine franchise grew 8% to $1.49bn, around $100m ahead of expectations, although analysts expressed concerns that Pfizer was at risk of falling behind in the race
Merck wins speedy FDA review for 15-valent pneumococcal vaccine
Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win
Solid Q1 results lift Pfizer as it waits for pipeline boost
More from news
Approximately 1 fully matching, plus 38 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia.
-
Deal Watch table for March 2014
26.6. ‡SK Chemicals/ Sanofi Pasteur. Collaboration. Pneumococcal conjugate vaccine (PCV). 23.
-
A tailored approach to the BRIC markets
In 2009, GSK signed a 1.5bn deal with the Brazilian government to provide Syflorix, its vaccine for paediatric pneumococcal disease, at around a third of the price it charged in ... Europe. The deal guaranteed GSK a set price and set volumes for the
20 for 2020 – Five pharma leaders to watch in 2020
Deal Watch table for March 2014
A tailored approach to the BRIC markets
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- New data from Moderna supports COVID boosters
- $47.5m research centre to seek genetic insights into disease
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Nicky Hutchens appointed as deputy managing director at Four Health
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- bluebird bio gears up for split
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- If the shoe fits
- Initiative Health welcomes Life Sciences by Stickyeyes
PMHub
Mednet Group
Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
